AstraZeneca Pharma

YEAR                                                    EVENTS
 1979 - The Company was incorporated on 11th July, and the Certificate
 of
        Commencement of Business was obtained on 6th November, 1979. 
 It
        was promoter jointly by Astra Pharmaceuticals AB, Sweden
 (Astra)
        and IDL Chemicals Ltd., Hyderabad (IDL).
 
 1980 - The Company entered into a technical collaboration with Astra
        Pharmaceuticals AB, Sweden for the supply for information and
        know-how and all manufacturing process and technical data for
 the
        manufacture of basic drugs, formulations, fine chemicals and
        industrial chemicals.
 
      - The Company undertook to set up a project at Yelahanka,
        Bangalore, for the manufacture of basic drugs, formulations,
 fine
        and industrial chemicals.  Pharmaceuticals and chemicals
 plant
        was commissioned in February 1982.
 
 1982 - 2,000 shares issued to promoters, etc. 24,98,000 shares issued
 at
        par; 6,43,235 shares each allotted to Astra Pharmaceuticals
 AB,
        Sweden and IDL Chemicals, Ltd.; 3,78,830 shares allotted to
        Indian directors, shareholders and employees, shareholders
 and
        employees, etc. of the company and also that of IDL
 Chemicals,
        Ltd. and 8,32,700 shares offered for public subscription
 during
        February-March, 1982.
 
 1988 - The Company launched `SENSORCAINE', a long acting local
        anaesthetic for use in surgical anaesthesia and introduced
        `THEOBRIC', a combination branco dilator for asthma.  The
 Company
        also planned to launch new products based on original research
 of
        Astra in the fields of peptic ulcer, hypertension and asthma.
 
      - The Company launched during the year `RESTOMYCIN', an
 antibiotic
        `BROMENYL', a cough expectorant and `FEBRAFEN' a pain and
 fever
        reliever.
 
      - The company was also in the process of creating in-house
        facilities for the manufacture of products based on
 inhalation
        therapy and formulation therapy and formulations based on
        prostaglandins.
 
      - The Company launched `PROSTODIN', the first protagladin with
 an
        important indication for postpartum haemorage, etc.  Several
 new
        products were launched during the year, namely, SELOPRES,
 BETALOC
        DURULES, TRIPRES, SENSORCAINE SPINAL and BRICANYL NEBULISING
        SOLUTION.  It also launched products based on inhalation
 therapy
        such as `PULMICORTINHALER' BRICANYL INHALER and SPACEHALER.
 
 1991 - The Company launched a product in the Prostaglandins range
        `PIMIPROST' for the promotion of safe motherhood.
 
 1992 - The Company launched Prostaglandin `Cerviprime Gel' for
        preinduction cervical ripening and `Plendil' a new generation
        calcium antagonist.  The Company proposed to launch `Ramace',
        `Rhinocort' and `Imdur'.
 
 1994 - Several new products were launched during the year, namely,
        Ramace and Imdur, which strengthen the cardiovascular range
 of
        products.  Similarly Rhinocort was introduced which is in the
        range of respiratory care products.
 
 1995 - 25,00,000 bonus shares issued in prop. 1:1.
 
 1996 - Two new line of extension namely `Jumbo' pack of Pulmicort &
        Bricanyl Inhalers 400 metered doses were introduced in the
        respiratory group.  A low dose aspirin formation to correct
        thromboembolic disorders was launched.  Also Imdur 30 mg to
        support Imdur 60 mg was introduced.
 
 1997 - A range of new products viz., Xylocaine Spray in pain control
        segment, Stop-it in Anti-infective segment, Mimbid in NSAID
        segment, Linctus-D and Rhinocort Aqua in Respiratory segment,
        Rejois in Maternal health care segment and Cellubril, a stool
        softner.
 
      - The company established state-of-the-art production
 facilities
        for aerosols and soft gelatin capsules near its formulations
        plant.
 
      - A joint venture between Astra AB of Sweden and IDL Industries
        of the Hindujas, Astra-IDL has been the subject of a
 prolonged
        litigation between the two promoters.
 
      - A joint venture between the US $ 7-billion Swedish
 pharmaceutical
        major Astra AB and IDL Industries of the Hindujas.
 
 1998 - Wipro, Honda Siel Power Products, and Astra-IDL have been
        conferred the Analyst Awards, by The Institute of Chartered
        Financial Analysts of India (ICFAI).
 
      - Astra had set up a 100 per cent research facility in
 Bangalore
        three years ago.
 
 1999 - Even as the Hindujas continue to seek new alignments to
 replace
        multinational AstraZeneca in their joint venture Astra-IDL
 Ltd.
 
 2000 - UB's 100 per cent subsidiary, UB Bioteck, has tied up with
 Astra
        IDL Ltd to market its newly-patented anti-obesity
 nutraceutical.
 
         - Mr. D.E. Udwadia, Director, has been appointed as the
 Chairman.
 
 2001 - Crisil has placed the `FAA' rating on the fixed deposit
 programme of the
              company on a `rating watch with positive implications'.
 
           - The Company upon the acquisition, Astra, Swden now holds
 51.50 per cent of the 
             company's issued and paid-up equity shares capital.  The
 company is therefore 
             a subsidiary of Astra, Swden and has become a part of the
 worldwide AstraZeneca Group.
 
           - The Managing Director, Mr. A.R. Hegde, has resigned from
 the company.
 
            - Astra-IDL Ltd will be renamed AstraZeneca Pharma India
 Ltd and Mr Lars Walan,
              recently designated Managing director, will take over on
 April 2 from Mr. A.R. 
              Hegde, MD, who has resigned.
 
 2002
 
 -Ties up with Avestha for research on discovering drug for
 tuberculosis.
 
 -Makes an open offer to acquire the balance 21,75,050 equity shares
 of Astrazeneca pharma India Ltd representing 43% stake.
 
 -Government okays FDI proposal for the company and Tata Homefinance
 from 56.69% to 100% accounting for Rs.82 crs.
 
 -Astra Pharma acquires 32800 equity shares of Astrazeneca.
 
 2003
 
 -Astra Pharma and Astrazeneca jointly acquires less than 4%
 additional equity Astrazeneca Pharma India Ltd. 
 
 -Sri Tom McKillop, inaugurates R & D centre in Bangalore at a cost of
  million.
 
 -Approaches Union government for Exclusive Marketing Rights for new
 two generation anti-cancer drugs.
 
 -Astrazeneca Pharma India Limited Board accepts resignation of Mr. J
 G Zetterberg, Director, effective from the close of May 05, 2004.
 
 2006
 
 -AstraZeneca acquires Eli Lilly's Vancocin brand
 
 2007
 
 -AstraZeneca Pharma India Ltd has appointed Mr. Ruud Dobber as
 Director of the Company.